Trial Profile

Surgical Excision Versus Curettage Prior to Imiquimod for the Treatment of Nodular Basal Cell Carcinoma: an Open, Non-inferiority, Randomized Controlled Trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imiquimod (Primary) ; Imiquimod (Primary)
Indications Basal cell cancer; Carcinoma
Focus Therapeutic Use
Acronyms SCIN

Most Recent Events

18 Jan 2024 Status changed from active, no longer recruiting to completed.
27 Apr 2020 New trial record
19 Apr 2020 Primary endpoint (Proportion of participants tumour-free) has not been met, according to Results published in the Journal of the American Academy of Dermatology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com